insights_auto
Why is ALNY up 2.55%?
Dive Deeperchevron_right
ALNY:NASDAQ
Alnylam Pharmaceuticals, Inc.
$255.96
arrow_upward
+2.55%(+6.37) 1D
$254.00
arrow_downward
-0.77% (-1.96)todayPre-market
Closed: Sep 25, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALNY...
Open
$248.39
High
$256.66
Low
$247.51
Mkt. cap
34.25B
Avg. vol.
1.61M
Volume
108.00
P/E ratio
43.56
52-wk high
$495.55
52-wk low
$197.81
EPS
$5.88
Beta
0.31
Shares outstanding
133.81M
No. of employees
2K
Open
$248.39
High
$256.66
Low
$247.51
Mkt. cap
34.25B
Avg. vol.
1.61M
Volume
108.00
P/E ratio
43.56
52-wk high
$495.55
52-wk low
$197.81
EPS
$5.88
Beta
0.31
Shares outstanding
133.81M
No. of employees
2K
News stories
From web sources and news partners
The Motley Fool
·
1 hour ago
18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right.
Investing.com Nigeria
·
22 hours ago
Form 4 Alnylam Pharmaceuticals Inc For: 27 September By Investing.com
Seeking Alpha
·
2 days ago
Alnylam Needs Stronger AMVUTTRA Execution To Justify More Upside (NASDAQ:ALNY)
Profile
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
About Alnylam Pharmaceuticals, Inc.